Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo

被引:13
作者
Belfrage, H [1 ]
Dohlsten, M [1 ]
Hedlund, G [1 ]
Kalland, T [1 ]
机构
[1] PHARMACIA & UPJOHN INC,LUND,SWEDEN
关键词
D O I
10.1046/j.1365-2567.1997.00030.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Administration of staphylococcal enterotoxin A (SEA) to mice induces profound activation, cytokine production and cytotoxic activity of both CD4(+) and CD8(+) T cells, but subsequently activated cells are deleted or become anergic. This study demonstrates that administration of interleukin-2 (IL-2) can prevent sea-induced hyporesponsiveness in CD8(+) cytotoxic T lymphocytes (CTL). Repeated injections with sea every fourth day resulted in severly reduced cytotoxic activity in the spleen, which correlated with a reduced number of sea-responsive T-cell receptor (TCR)-V beta 11(+)CD8(+) cells. Studies of purified TCR-V beta 11(+)CD8(+) cells showed that they possessed intact cytotoxic activity per cell compared with cells from mice given a single injection of SEA, indicating that deletion was the main mechanism for the reduced cytotoxic activity. Combined treatment with SEA and IL-2 increased the number of cytotoxic cells in the spleen after each SEA injection and prevented the down-regulation of cytotoxic activity. Increased cytotoxic activity could be related to increased number and proliferation of CD8(+)IL-2R alpha(+) cells, suggesting that administration of IL-2 maintained IL-2 responsiveness among CD8(+) cells. Studies of sorted TCR-V beta 11(+)CD8(+) cells demonstrated that combined treatment with SEA and IL-2 also increased cytotoxic activity per cell compared with treatment with SEA alone. Taken together, IL-2 administration in vivo augmented SEA-induced expansion of T cells as well as the cytotoxic activity per CTL, and prevented SEA-induced cell deletion.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 32 条
[1]  
BELFRAGE H, 1995, CANCER IMMUNOL IMMUN, V41, P87
[2]   REVERSAL OF INVITRO T-CELL CLONAL ANERGY BY IL-2 STIMULATION [J].
BEVERLY, B ;
KANG, SM ;
LENARDO, MJ ;
SCHWARTZ, RH .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (06) :661-671
[3]   PREVENTION OF T-CELL ANERGY BY SIGNALING THROUGH THE GAMMA(C) CHAIN OF THE IL-2 RECEPTOR [J].
BOUSSIOTIS, VA ;
BARBER, DL ;
NAKARAI, T ;
FREEMAN, GJ ;
GRIBBEN, JG ;
BERNSTEIN, GM ;
DANDREA, AD ;
RITZ, J ;
NADLER, LM .
SCIENCE, 1994, 266 (5187) :1039-1042
[4]   B7 BUT NOT INTERCELLULAR-ADHESION MOLECULE-1 COSTIMULATION PREVENTS THE INDUCTION OF HUMAN ALLOANTIGEN-SPECIFIC TOLERANCE [J].
BOUSSIOTIS, VA ;
FREEMAN, GJ ;
GRAY, G ;
GRIBBEN, J ;
NADLER, LM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (05) :1753-1763
[5]   POTENTIAL USES OF INTERLEUKIN-2 IN CANCER-THERAPY [J].
CHEEVER, MA ;
THOMPSON, JA ;
PEACE, DJ ;
GREENBERG, PD .
IMMUNOBIOLOGY, 1986, 172 (3-5) :365-382
[6]   PERIPHERAL TOLERANCE TO ALLOANTIGEN RESULTS FROM ALTERED REGULATION OF THE INTERLEUKIN-2 PATHWAY [J].
DALLMAN, MJ ;
SHIHO, O ;
PAGE, TH ;
WOOD, KJ ;
MORRIS, PJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (01) :79-87
[7]   CELL-MEDIATED CYTOTOXICITY [J].
DOHERTY, PC .
CELL, 1993, 75 (04) :607-612
[8]  
DOHLSTEN M, 1993, IMMUNOLOGY, V79, P520
[9]   MONOCLONAL ANTIBODY-TARGETED SUPERANTIGENS - A DIFFERENT CLASS OF ANTITUMOR AGENTS [J].
DOHLSTEN, M ;
HEDLUND, G ;
AKERBLOM, E ;
LANDO, PA ;
KALLAND, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (20) :9287-9291
[10]   MONOCLONAL ANTIBODY-SUPERANTIGEN FUSION PROTEINS - TUMOR-SPECIFIC AGENTS FOR T-CELL-BASED TUMOR-THERAPY [J].
DOHLSTEN, M ;
ABRAHMSEN, L ;
BJORK, P ;
LANDO, PA ;
HEDLUND, G ;
FORSBERG, G ;
BRODIN, T ;
GASCOIGNE, NRJ ;
FORBERG, C ;
LIND, P ;
KALLAND, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (19) :8945-8949